Anti-arthritis drug, Milican inj. on clinical phase IIb.

Published: 2001-02-01 17:31:00

Updated: 2001-02-01 17:31:00

Dongwha Pharmaceutical company announced that Milican inj. a new anti-rheumatoid arthritis agent, completed its clinical phase I and IIa studies, and the phase IIb study seemed to follow soon according to the KFDA's approval.

Milican inj. has been developed by Dongwha in technical cooperation ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK